Cisplatin Injection, Solution
NDC 72266-252
Product Information
Cisplatin is a ANDA-approved product labeled by Fosun Pharma Usa Inc. Cisplatin is used to treat various types of cancer. It is supplied as a injection, solution for intravenous administration. This product entry covers the primary NDC 72266-252 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 72266-252?
What are the uses of this product?
What are Active Ingredients of this product?
- CISPLATIN 1 mg/mL - An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- CISPLATIN (UNII: Q20Q21Q62J)
- CISPLATIN (UNII: Q20Q21Q62J) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- SODIUM CHLORIDE (UNII: 451W47IQ8X)
- HYDROCHLORIC ACID (UNII: QTT17582CB)
- SODIUM HYDROXIDE (UNII: 55X04QC32I)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 309311 - CISplatin 1 MG/ML Injectable Solution
- RxCUI: 309311 - cisplatin 1 MG/ML Injectable Solution
- RxCUI: 309311 - cisplatin 100 MG per 100 ML Injectable Solution
- RxCUI: 309311 - cisplatin 50 MG per 50 ML Injectable Solution
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.